Positive clinical results of ACP-001 presented at EHA2022
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate drug was presented at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].The abstract, titled “Autologous NK Cells as Consolidation After Front-Line Stem Cell Transplantation in Multiple Myeloma: A Long-Term Follow-Up”, was presented at a poster session by Dr Johan Aschan on Friday, June 10[th], 16:30 - 17:45 CEST. Co-authors include Johan Lund, Hareth Nahi, Stephan Meinke,